All News
A Convergence of Ideas: COVID19 and ACR
Since the beginning of the pandemic, rheumatologists scrambled to figure out how the SARS-CoV-2 virus will affect their patients with immune mediated inflammatory diseases (IMID). Meeting the needs of patients, managing a practice, and trying to balance a home life have many doctors stressed.
Read Article
New drug mechanisms for SpA. Nice to have expanding options
#ACR20 https://t.co/vlTwaiuuS3
Dr Irwin Lim _connectedcare ( View Tweet)
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
cirrhosis NNH 1000
5.LoDoCo2: colchicine prevents MACE: NNT 36
6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ:
NNH 600
k dao KDAO2011 ( View Tweet)
Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use.
Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer.
#ACR20 @RheumNow https://t.co/hNS600Pndr
Mrinalini Dey DrMiniDey ( View Tweet)
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow
Eric Dein ejdein1 ( View Tweet)
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Kevin Wei's study with @ilyakorsunsky @Deepakarao @soumya_boston, Dr. Michael Brenner and others at @BrighamResearch featured in the basic year-in-review at #ACR20 showing Notch signaling importance in synovium from arthritis #ACRambassador
Jeff Sparks jeffsparks ( View Tweet)
What is most important clinical study in last year? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
Peter Nash drpnash ( View Tweet)
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
Peter Nash drpnash ( View Tweet)
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat
Peter Nash drpnash ( View Tweet)
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
Peter Nash drpnash ( View Tweet)
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
American College of Rheumatology ACRheum ( View Tweet)
Our daily update is published. States reported record numbers of tests (1.5 million) and cases (116k). Hospitalizations continue their sharp rise. The death toll was 1,124. https://t.co/z3gxwP6EaC
The COVID Tracking Project COVID19Tracking ( View Tweet)
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/
ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)
One of the many HOT sessions tomorrow #ACR20 I am planning on - IFN is center stage in autoinflammatory/autoimmune/infectious diseases especially-hope they cover IFN autoantibodies!! #COVID19 - @CCalabreseDO @JYazdanyMD @canallab @MaxKonigMD @AdamJBrownMD @TiphaineLft https://t.co/uDauMkGsjX
Leonard Calabrese LCalabreseDO ( View Tweet)
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit
Peter Nash drpnash ( View Tweet)
Very psyched for this session tomorrow at #ACR20 on irAEs- this was a win for Twitter big time-thnxs for the shout out!!! looking for the next cut of data from the @rheum_covid alliance !!! @RheumNow @drdavidliew @CCalabreseDO @cappelliMD @HealioRheum https://t.co/qepFdLhmlV https://t.co/1jSek0sRqT
Links:
Leonard Calabrese LCalabreseDO ( View Tweet)
Happening now! Session 1T001 Opening Session of #ACR20. #ACRambassador Head on over, @ACRheum! https://t.co/eErNDB8pV6
Christina Downey, MD, RhMSUS cdowneymd ( View Tweet)
#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
Richard Conway RichardPAConway ( View Tweet)
